Connection

MARC HOROWITZ to Antineoplastic Agents

This is a "connection" page, showing publications MARC HOROWITZ has written about Antineoplastic Agents.
Connection Strength

0.255
  1. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
    View in: PubMed
    Score: 0.126
  2. Benefit from prolonged dose-intensive chemotherapy for infants with malignant brain tumors is restricted to patients with ependymoma: a report of the Pediatric Oncology Group randomized controlled trial 9233/34. Neuro Oncol. 2014 Mar; 16(3):457-65.
    View in: PubMed
    Score: 0.058
  3. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
    View in: PubMed
    Score: 0.018
  4. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995 Jan 19; 332(3):143-9.
    View in: PubMed
    Score: 0.016
  5. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994 Oct 01; 84(7):2221-8.
    View in: PubMed
    Score: 0.015
  6. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the multiinstitutional osteosarcoma study. J Clin Oncol. 1991 Apr; 9(4):600-5.
    View in: PubMed
    Score: 0.012
  7. Cancer chemotherapy-induced tubular nephrotoxicity evaluated by immunochemical determination of urinary adenosine deaminase binding protein. Am J Clin Pathol. 1986 Dec; 86(6):780-3.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.